The World Trade Organization’s (WTO’s) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) calls for the harmonization of intellectual property rights (IPRs) regulations across all WTO member countries. The TRIPS Agreement requires all WTO member countries to adopt and enforce minimum standards of intellectual property. It was assumed that the introduction of pharmaceutical product patents would hamper the Indian pharmaceutical industry’s growth. Contrary to expectations, however, the Indian pharmaceutical industry has been growing in the post-TRIPS period. The TRIPS Agreement changed the research and development (R&D) orientation of Indian pharmaceutical companies, which have increased their R&D investments. Since the TRIPS Agreement was signed, the pharmaceutical global value chain (GVC) has been re-structured and has now expanded to emerging countries like India. Indian pharmaceutical firms have thus been participating in the pharmaceutical GVC in the post-TRIPS period. This participation is conducive to technological upgrading and technology transfers. While operating in the GVC, Indian pharmaceutical firms are upgrading by adopting state-of-the-art technologies. This study explores how the TRIPS Agreement is influencing the Indian pharmaceutical industry and discusses the industry’s growth factors in the post-TRIPS period within the GVC framework.

JEL: L21, L24, L26, L65

世界贸易组织（WTO）的《与贸易有关的知识产权协议》（TRIPS协议）要求在所有WTO成员国之间统一知识产权法规。TRIPS协议要求所有WTO成员国采用并执行最低限度的知识产权标准。人们认为，引入药品专利将阻碍印度制药业的发展。然而，与预期相反，印度的制药业在TRIPS后时期一直在增长。TRIPS协议改变了印度制药公司的研发方向，从而增加了其研发投资。自从《 TRIPS协议》签署以来，制药全球价值链（GVC）已进行了重组，现已扩展到印度等新兴国家。因此，印度制药公司在TRIPS后时期一直参与制药GVC。这种参与有利于技术升级和技术转让。在GVC中运营时，印度制药公司正在通过采用最先进的技术进行升级。这项研究探讨了《 TRIPS协定》如何影响印度制药业，并探讨了在GVC框架内，TRIPS后时期该产业的增长因素。这种参与有利于技术升级和技术转让。在GVC中运营时，印度制药公司正在通过采用最先进的技术进行升级。这项研究探讨了《 TRIPS协议》如何影响印度制药业，并探讨了在GVC框架内，TRIPS后时期该行业的增长因素。这种参与有利于技术升级和技术转让。在GVC中运营时，印度制药公司正在通过采用最先进的技术进行升级。这项研究探讨了《 TRIPS协议》如何影响印度制药业，并探讨了在GVC框架内，TRIPS后时期该行业的增长因素。

JEL：L21，L24，L26，L65